Singapore markets close in 3 hours 7 minutes
  • Straits Times Index

    +10.98 (+0.35%)
  • Nikkei

    +600.65 (+2.15%)
  • Hang Seng

    +430.90 (+1.85%)
  • FTSE 100

    +109.96 (+1.54%)

    +2,201.61 (+4.51%)
  • CMC Crypto 200

    +58.36 (+4.63%)
  • S&P 500

    +53.24 (+1.17%)
  • Dow

    +646.95 (+1.87%)
  • Nasdaq

    +139.68 (+0.93%)
  • Gold

    +0.20 (+0.01%)
  • Crude Oil

    +0.88 (+1.27%)
  • 10-Yr Bond

    -1.4340 (-100.00%)
  • FTSE Bursa Malaysia

    +5.90 (+0.40%)
  • Jakarta Composite Index

    +45.62 (+0.70%)
  • PSE Index

    -14.75 (-0.21%)

Omicron’s rapid spread shreds budding recovery in air travel

Eupraxia Pharmaceuticals Inc. Announces Presentation at H.C. Wainwright 23rd Annual Global Investment Conference

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

VICTORIA, BC, Sept. 8, 2021 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery platform technology, today announced that senior management will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference, held virtually September 13-15, 2021.

The Company's on-demand presentation will be available starting on Monday, September 13, 2021, at 7:00 AM ET. Eupraxia invites all interested parties to view the presentation by clicking the following link:

Eupraxia CEO Dr. James Helliwell will provide an overview of the Company's business during the presentation, and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

About Eupraxia

Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. Each of Eupraxia's product candidates has the potential to address therapeutic areas with high unmet medical need and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects.

Eupraxia's lead product candidate, EP-104IAR, is currently in Phase 2 development for the treatment of pain due to OA of the knee. In addition to EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. Potential pipeline candidates include a range of drugs for indications such as post-surgical pain (EP-105), and post-surgical site infections (EP-201), each designed to improve on the activity and tolerability of approved drugs. Eupraxia is also developing a formulation of EP-104IAR for use in canine and equine OA.

For further details about Eupraxia, please visit the Company's website at:

SOURCE Eupraxia Pharmaceuticals Inc.


View original content:

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting